Lineage extends cash runway into Q2 2027 as OpRegen site expansion accelerates and new partnerships advance pipeline
Source: SeekingAlpha
2025-11-06 22:07:03 ET
More on Lineage Cell Therapeutics
- Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript
- Lineage Cell Therapeutics, Inc. (LCTX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript
- Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript
- Lineage Cell Therapeutics Q3 2025 Earnings Preview
- Lineage signals expanded diversification strategy following OpRegen milestones and $42.3M cash position
Read the full article on Seeking Alpha
For further details see:
Lineage extends cash runway into Q2 2027 as OpRegen site expansion accelerates and new partnerships advance pipeline
Lineage Cell Therapeutics, Inc.
NASDAQ: LCTX
LCTX Trading
-5.57% G/L:
$1.78 Last:
283,129 Volume:
$1.80 Open:
LCTX Latest News
March 05, 2026 04:01:00 pm
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026 08:00:00 am
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
January 29, 2026 01:31:00 pm
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
January 06, 2026 08:00:00 am
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
LCTX Stock Data
$424,954,306
168,599,757
0.11%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
Carlsbad
